Lataa...
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small molecule inhibitor of ALK, ROS1 and MET. Unfortunately, the disease progressed within the first 12 months in...
Tallennettuna:
| Julkaisussa: | Ther Adv Med Oncol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4699265/ https://ncbi.nlm.nih.gov/pubmed/26753004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834015617355 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|